ArticleInternational journal of pharmaceutics: X2025
Bioinspired pH-sensitive liposomes for quercetin delivery to synergize with 5- FU in gastric cancer therapy.
Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is a major cause of cancer-related mortality on a global scale. Although 5-fluorouracil (5-FU) is a cornerstone chemotherapeutic for digestive tract malignancies, its efficacy is limited by dose-dependent toxicity and acquired resistance. Quercetin (QUC), a natural flavonoid, can sensitize tumor cells to 5-FU by modulating cell cycle-regulatory proteins. However, its limited water solubility and low bioavailability present significant limitations on its potential therapeutic application. In this study, we developed bioinspired pH-sensitive liposomes (NK-Lip@Q) functionalized for active targeting and acid-triggered drug release to enhance QUC delivery and synergistic anticancer activity with 5-FU. NK-Lip@Q exhibited a mean particle size of 206.36 ± 1.81 nm, an encapsulation efficiency of 60.69 ± 1.32 %, and a pH-dependent release profile with 72.75 ± 0.69 % cumulative release at pH 5.4. Cellular studies demonstrated efficient uptake by N87 cells, marked apoptosis induction (apoptosis ratio: 69.60 ± 8.71 %), and enhanced cytotoxicity in combination with 5-FU (Chou-Talalay combination index, CI = 0.68). In vivo, NK-Lip@Q could precisely accumulate in the target area, when co-administered with 5-FU, achieved significant tumor inhibition (tumor inhibition rate: 92.26 %) without obvious systemic toxicity. QUC complemented the anticancer action of 5-FU by regulating cell cycle-related genes, promoting apoptosis, and suppressing proliferation. In conclusion, this study demonstrates that NK-Lip@Q as a promising nanocarrier system that enhances the therapeutic performance of 5-FU by improving its synergistic antitumor efficacy in gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.